NCT06748001RecruitingPhase 4
Avapritinib Rollover Study
An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 19 Dec 2024
- Start date
- 28 Nov 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Blueprint Medicines Corporation
- NCT number
- NCT06748001
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 60
- From 28 Nov 2024 to the primary completion date, 31 Dec 2027
- 7 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participant is participating in another interventional study.
- Participant is unwilling or unable to comply with study procedures and study restrictions.
- Participant is breastfeeding.
- Other protocol-defined criteria apply.
Who the study is looking for
- Participated in a Blueprint Medicines sponsored avapritinib clinical study. The Sponsor reserves the right to not roll over patients who have been on drug hold for an extended time period.
- Completed End of Trial / End of Study (EOT/EOS) visit in the parent study and demonstrated compliance with the parent study requirements.
- Continue to clinically benefit from treatment with avapritinib.
- Able to give written informed consent.
- Agree to continue to use highly effective contraception as defined in this protocol.
- Female patients of childbearing potential must have negative highly sensitive serum pregnancy test within 20 days before the first dose of avapritinib. Women of nonchildbearing potential do not require this test.
Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Ziekenhuis Antwerpen (Uza) Coordinator of this site? Confirm its status | Edegem | Belgium | Recruiting |
| The Hospital for Sick Children Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Guys and St Thomas NHS Foundation Trust - St Thomas Hospital Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno Coordinator of this site? Confirm its status | Salerno | Italy | Recruiting |
| Universitair Medisch Centrum Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
| Erasmus Medisch Centrum Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Recruiting |
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.